Merrimack Pharmaceuticals (MACK) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free MACK Stock Alerts $14.73 +0.02 (+0.14%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMACK Merrimack Pharmaceuticals, Inc.seekingalpha.com - April 20 at 8:40 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Passes Above 200 Day Moving Average of $13.50americanbankingnews.com - April 20 at 2:32 AMDiagonal starts up with $128M to make better ‘activator’ antibody drugsfinance.yahoo.com - April 3 at 4:07 PMMerrimack Receives $225 Million Milestone Payment from Ipsenbusinesswire.com - March 27 at 4:30 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200 Day Moving Average of $13.19marketbeat.com - March 26 at 4:11 AMMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Sees Large Drop in Short Interestmarketbeat.com - March 18 at 8:30 AMStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cutsmsn.com - March 8 at 3:41 PMMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023investorplace.com - March 8 at 10:02 AMMerrimack Reports Full Year 2023 Financial Resultsbusinesswire.com - March 7 at 4:30 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.93marketbeat.com - March 5 at 5:47 AMMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyfinance.yahoo.com - March 4 at 7:39 AMMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, Predictionsbenzinga.com - February 22 at 12:38 PMMACK Mar 2024 14.000 putfinance.yahoo.com - February 17 at 7:50 PMMACK Mar 2024 4.000 putfinance.yahoo.com - February 17 at 2:49 PMOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officermarkets.businessinsider.com - February 15 at 1:03 PMMACK Feb 2024 16.000 putfinance.yahoo.com - February 14 at 8:47 PMIpsen drug approved by FDA for early pancreatic cancerfinance.yahoo.com - February 14 at 3:42 PMThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsmsn.com - February 13 at 7:31 PMMerrimack Pharmaceuticals to Hold Meeting on Corporate Dissolutionmarketwatch.com - February 13 at 7:31 PMMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)finance.yahoo.com - February 13 at 7:31 PMMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)businesswire.com - February 13 at 4:18 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.65marketbeat.com - February 13 at 4:17 AMMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.55marketbeat.com - January 31 at 2:57 AMMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded at StockNews.commarketbeat.com - January 31 at 1:26 AMMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded by StockNews.commarketbeat.com - January 23 at 10:18 PMMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Eric Andersen Purchases 857 Sharesmarketbeat.com - December 28 at 6:45 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded to Hold at StockNews.commarketbeat.com - December 27 at 10:14 PM$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buyingmsn.com - December 12 at 4:43 PMWe're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Growfinance.yahoo.com - December 10 at 12:03 PMMerrimack Pharmaceuticals Inc MACKmorningstar.com - November 10 at 11:39 PMMerrimack Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 2 at 7:27 PMOnconova Expands Leadership Team with Two Key Appointmentsstockhouse.com - October 24 at 8:53 AMThe Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firmtheglobeandmail.com - October 20 at 12:43 PMWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals Incfinance.yahoo.com - August 15 at 3:36 PMOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcriptinsidermonkey.com - August 13 at 8:09 AMMerrimack Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 3 at 8:17 PMPharming Group N.V.: Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Boardfinanznachrichten.de - July 18 at 1:19 AMPharming to nominate industry leader Dr. Richard Peters as new Chairman of the Boardfinance.yahoo.com - July 18 at 1:19 AMMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Rating Lowered by StockNews.commarketbeat.com - July 7 at 10:15 PMMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded to "Sell" at StockNews.commarketbeat.com - June 23 at 10:15 PMMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is 22Nw LP's 6th Largest Positionmarketbeat.com - May 26 at 2:28 PMShort Interest in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases By 6.7%marketbeat.com - May 2 at 3:48 AMRetail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds account for 33%finance.yahoo.com - April 19 at 7:33 AMGlobal Receptor Tyrosine Protein Kinase ERBB 3 Market Size Emerging Trends and Will Generate New Growth Opportunities Status 2030 By VMReportsmarketwatch.com - April 16 at 12:29 AMMerrimack Valley High Schoolusnews.com - April 15 at 7:26 PMWhy Merrimack Pharmaceuticals (MACK) Stock is Down in After-Hours Trading Todaythestreet.com - April 3 at 8:58 AMTrack Covid-19 in Merrimack County, New Hampshirenytimes.com - March 30 at 11:21 PMOncology Injection Drug Market Size and Forecast till 2031marketwatch.com - March 22 at 3:10 PMWhy Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarketmsn.com - March 15 at 12:41 PMMerrimack Won a Title, but the N.C.A.A. Tournament Will Have to Waitnytimes.com - March 10 at 11:49 PM Get Merrimack Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> MACK Media Mentions By Week MACK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MACK News Sentiment▼0.300.41▲Average Medical News Sentiment MACK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MACK Articles This Week▼20▲MACK Articles Average Week Get Merrimack Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACRV News IMMP News THRX News PRQR News NGM News KNTE News ASMB News VTVT News BYSI News AVRO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MACK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
